Trends in Bacterial Distribution and Antimicrobial Resistance in Intensive Care Units of Hubei Province, China: A Four-year Surveillance Study (2020–2023)

Abstract

Objective

To investigate the distribution characteristics of common bacteria and changes in antimicrobial resistance in intensive care unit (ICU) patients in 58 hospitals in Hubei Province from 2020–2023.

Method

The antimicrobial agents for antimicrobial susceptibility tests was selected based on the 2022 China Antimicrobial Resistance surveillance system (CARSS) technical scheme, and the specific experimental operation was based on the requirements of the CLSI M02 and M07 documents. The commercial instruments were used following the manufacturer’s instructions. The interpretation of antimicrobial susceptibility test results was based on the 2023 CLSI M100 standard.

Results

There were 15 585, 19 258, 23 423 and 22 395 clinical isolates in the ICU from 2020 to 2023, respectively. Among them, gram-positive bacteria accounted for 20.5% (3190/15 585), 21.2% (4089/19 258), 21.6% (5067/23 423) and 21.6% (4 831/22 395), respectively. Gram-negative bacteria accounted for 79.5% (12 395/15 585), 78.8% (15 169/19 258), 78.4% (18 356/23 423) and 78.4% (17 564/22 395) of the bacteria, respectively. The top 5 isolates of gram-positive bacteria were Staphylococcus aureus, Enterococcus faecium, Streptococcus pneumoniae, Enterococcus faecalis, Staphylococcus epidermidis and gram-negative bacteria were Klebsiella pneumoniae, Acinetobacter baumannii, Escherichia coli, Pseudomonas aeruginosa and Stenotrophomonas maltophil, respectively, but the proportions and rankings of the isolates in different years slightly differed. The detection rate of methicillin-resistant S. aureus (MRSA) decreased from 44.4% in 2020 to 36% in 2023, and that of methicillin-resistant coagulase-negative Staphylococcus (MRCNS) decreased from 79.8% in 2020 to 73.8% in 2022 and increased to 78.4% in 2023. The detection rates of both vancomycin-resistant E. faecium and E. faecalis were lower than 1%. The detection rate of carbapenem-resistant P. aeruginosa (CRPA) decreased from 25% in 2020 to 19.7% in 2022 and increased slightly to 20.6% in 2023. The detection rate of carbapenem-resistant A. baumannii (CRAB) decreased from 81.9% in 2020 to 79.7% in 2022 and increased to 82.9% in 2023. The detection rate of third-generation cephalosporin-resistant E. coli decreased from 59.8% in 2020 to 53.1% in 2022 and increased to 52.5% in 2023. The detection rate of fluoroquinolone-resistant E. coli decreased from 62.7% in 2020 to 50.2% in 2022 and increased slightly to 51.0% in 2023. The detection rate of carbapenem-resistant E. coli (CRECO) decreased from 3.3% in 2020 to 1.8% in 2022 and slightly increased to 2.1% in 2023. The detection rate of third-generation cephalosporin-resistant K. pneumoniae decreased from 34.3% in 2020 to 26.3% in 2022 and then increased to 32.4% in 2023. The detection rate of carbapenem-resistant K. pneumoniae (CRKPN) increased from 17.9% to 19.4% in 2020, decreased to 13.2% in 2022, and rose sharply to 20.4% in 2023.

Conclusion

MRSA showed a continuous downwards trend from 2020 to 2023, while the detection rates of MRCNS and most multidrug-resistant gram-negative bacteria continuously decreased from 2020 to 2022 but tended to increase in 2023. Therefore, it is still necessary to strengthen the monitoring of bacterial resistance and rational application of antibiotics and actively and effectively control nosocomial infections.

References

[1] World Health Organization. Global tuberculosis report 2022, 2022 Published October

[2] Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet, 2022, 399(10325): 629-655

[3] VincentJL, SakrY, SingerM, et al. . Prevalence and outcomes of infection among patients in intensive care units in 2017. JAMA, 2020, 323(15): 1478-1487

[4] AliM, NaureenH, TariqMH, et al. . Rational use of antibiotics in an intensive care unit:a retrospective study of the impact on clinical outcomes and mortality rate. Infect Drug Resist, 2019, 12: 493-499

[5] China Antimicrobial Susceptibility Surveillance System. The technical scheme of China Antimicrobial Resistance Surveillance System (China), 2024 Published April

[6] CLSI. CLSI M100. Performance Standards for Antimicrobial Susceptibility Testing, 2024 34 Wayne, PA Clinical and Laboratory Standards Institute

[7] China Antimicrobial Resistance Surveillance System. Antimicrobial resistance surveillance report from intensive care units from China Antimicrobial Resistance Surveillance System. Chin J Infect Control, 2023, 33(23): 3370-3379 (Chinese)

[8] ChenLH, FuCC, LiC, et al. . Antimicrobial resistance of bacteria from intensive care units: surveillance report from Hunan Province Antimicrobial Resistance Surveillance System, 2012–2021. Chin J Infect Control, 2024, 23(8): 942-953 (Chinese)

[9] Weiner-LastingerLM, AbnerS, EdwardsJR, et al. . Antimicrobial-resistant pathogents associated with adult healthcare-associated infections: summary of data reported to the natioal Healthcare Safety Network, 2015–2017. Infect Control Hosp Epidemiol, 2020, 41(1): 1-18

[10] SanderHS, MendesRE, StreitJM, et al. . Antimicrobial susceptibility of Gram-negative bacteria from intensive care unit and non-intensive care unit patients from United States hospitals (2018–2020). Diagn Microbiol Infect Dis, 2022, 102(1): 115557

[11] China Antimicrobial Resistance Surveillance System. Antimicrobial resistance of bacteria: surveillance report from China Antimicrobial Resistance Surveillance System in 2014–2019. Chin J Infect Control, 2021, 20(1): 15-31 (Chinese)

[12] HanRR, ShiQY, WuS, et al. . Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among Carbapenem-Resistant Enterobacteriaceae Isolated from Adult and Children Patients in China. Front Cell Infect Microbiol, 2020, 10: 314

[13] U.S. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019

[14] WangLC, ZhouKH, ChenW, et al. . Epidemiology and risk factors for nosomial infection in the respiratory intensive care unit of a teaching hospital in China: a prospective surveillance during 2013 and 2015. BMC Infect Dis, 2019, 19(1): 145

[15] HolmesAH, MooreLSP, SundsfjordA, et al. . Understanding the mechanisms and drivers of antimicrobial resistance. Lancet, 2016, 387(10014): 176-187

[16] McEwen SA, Collignon PJ. Antimicrobial Resistance: a One Health Perspective. Microbiol Spectr, 2018,6(2). doi: https://doi.org/10.1128/microbiolspec.ARBA-0009-2017.

[17] AslamB, KhurshidM, ArshadMI, et al. . Antibiotic Resist ance: One Health One World Outlook. Front Cell Infect Microbiol, 2021, 11: 771510

RIGHTS & PERMISSIONS

Huazhong University of Science and Technology